Lucy Coutts
Canadainvestment directorFemale5.0Global Dominance: 0.00%Lucy Coutts is an investment director at JM Finn and a shareholder in AstraZeneca. She has expressed skepticism regarding the potential merger between AstraZeneca and Bristol Myers Squibb, suggesting that the only notable advantage for AstraZeneca would be to enhance its U.S. market presence, while indicating that such a deal would likely be more beneficial for Bristol Myers shareholders.
Power1,534
Reach34,301
Country presence
Recent news mentions
Lucy Coutts commented on the potential merger between AstraZeneca and Bristol Myers Squibb.
AstraZeneca investors punish firm over reports of $400-billion Bristol Myers pharma dealThe Globe and Mail·Canada· 2026-08-03
Canada· 2026-08-03
